Moderna says FDA will delay its vaccine use for children aged 12 to 17 to continue evaluations of myocarditis risk - or inflammation of the heart muscle - until at least January 2022.
The FDA authorized Pfizer-BioNTech s COVID-19 vaccine for emergency use among children betwen ages five and 11 on Friday and the first shots are expected to roll out next week.